Penumbra, Inc.

Report azionario NYSE:PEN

Capitalizzazione di mercato: US$12.8b

Penumbra Crescita futura

Criteri Future verificati 2/6

Penumbra prevede che gli utili e i ricavi cresceranno rispettivamente di 17.9% e 10.9% all'anno. Si prevede che l'EPS crescerà di 17.5% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 12.8% in 3 anni.

Informazioni chiave

17.9%

Tasso di crescita degli utili

17.49%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili17.3%
Tasso di crescita dei ricavi10.9%
Rendimento futuro del capitale proprio12.84%
Copertura analitica

Good

Ultimo aggiornamento05 Aug 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Aggiornamento narrativa • Jul 16

PEN: Merger Progress And Stroke Trial Data Will Shape Fair Outlook

Analysts have raised their price target on Penumbra to about $325 from roughly $239, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E, which collectively support a higher estimated valuation range for the stock. What’s in the News for Penumbra Penumbra shareholders approved the proposed merger with Boston Scientific Corporation at a special meeting on May 6, 2026, including compensation arrangements for named executive officers, according to recent shareholder meeting results.
Aggiornamento narrativa • Jul 01

PEN: Stroke Device Approvals And Merger Outlook Will Drive Future Upside

Analysts have adjusted their price target for Penumbra to $374 from $355, citing updated assumptions related to discount rates, revenue growth, profit margins, and future P/E expectations. What’s in the News for Penumbra Penumbra received U.S. FDA clearance and European CE Mark approval for its THUNDERBOLT computer assisted vacuum thrombectomy system for acute ischemic stroke, the first CAVT platform approved in the U.S. specifically for stroke care, according to recent news reports.
Articolo di analisi • Jun 19

Penumbra (PEN) Stock Could Be 12.7% Undervalued On STORM PE Trial Hopes

Penumbra (PEN) is back in focus after recent trading left the stock around $317.20, prompting investors to reassess its performance over the past month and past 3 months. See our latest analysis for Penumbra. Looking beyond the latest move, Penumbra’s 1 year total shareholder return of 23.42% contrasts with a year to date share price return of 2.51%, while the 3 year total shareholder return has declined 6.7%. This suggests that momentum has cooled after stronger recent gains. If you are...
Aggiornamento narrativa • Jun 17

PEN: Pulmonary Embolism Trial And Merger Approval Will Support Stronger Outlook

Analysts have maintained their Penumbra price target at approximately $363, noting only minor adjustments to factors such as the discount rate, assumptions about long-term revenue growth and profit margins, and the projected future P/E multiple. What’s in the News for Penumbra Boston Scientific announced plans to acquire Penumbra, with Artisan Partners highlighting the deal as confirmation of its prior investment thesis in Penumbra stock and using the transaction to exit its position.
Aggiornamento narrativa • Jun 03

PEN: Positive Pulmonary Embolism Trial Outcomes Will Support A Stronger Forward Outlook

Analysts have slightly trimmed their price target on Penumbra to $363.36 from $365.79, reflecting updated assumptions around the discount rate, revenue growth, profit margins, and future P/E. What's in the News Penumbra reported 90 day results from the STORM-PE randomized controlled trial, where patients with acute intermediate high risk pulmonary embolism treated with computer assisted vacuum thrombectomy (CAVT) plus anticoagulation showed greater functional improvement than those on anticoagulation alone, including longer six minute walk distances and a higher share reaching NYHA Class I, according to data presented at the Society of Interventional Radiology Annual Scientific Meeting.
Aggiornamento narrativa • Apr 25

PEN: Trial Outcomes And Steady Assumptions Will Shape Balanced Forward Outlook

Analysts have maintained their price target on Penumbra at $365.79, making only minor adjustments to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions to reflect updated views on the company’s risk profile and earnings potential. What's in the News Ninety-day results from the STORM-PE randomized controlled trial showed that patients with acute intermediate high risk pulmonary embolism treated with computer assisted vacuum thrombectomy plus anticoagulation walked longer distances in the six minute walk test, reached higher predicted walk distances, and had a higher share of patients with no physical limitations compared with anticoagulation alone, with broadly comparable safety outcomes through 90 days (Key Developments).
Aggiornamento narrativa • Apr 08

PEN: Merger Terms And Steady Assumptions Will Shape Balanced Forward Outlook

Analysts have raised their price target for Penumbra to $365.79 from $360.13, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E that together support a slightly higher valuation framework. What's in the News Boston Scientific Corporation agreed to acquire Penumbra for US$14.8b under a definitive merger agreement announced on January 14, 2026.
Aggiornamento narrativa • Mar 25

PEN: Merger Agreement And Steady Metrics Will Shape Measured Forward Outlook

Analysts have kept their $360.13 price target for Penumbra broadly unchanged, citing slightly adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E. Taken together, these changes leave their overall valuation view steady for now.
Aggiornamento narrativa • Mar 11

PEN: Proposed Buyout Terms And Revised Assumptions Will Shape Balanced Outlook

Analysts have nudged their price target on Penumbra higher to about $360 from roughly $349, citing updated assumptions that combine slightly lower revenue growth and a modestly lower future P/E with a somewhat higher profit margin outlook and a small adjustment to the discount rate. What's in the News Boston Scientific agreed to acquire Penumbra in a cash and stock deal valued at about US$14.8b, pricing each Penumbra share at US$374.
Aggiornamento narrativa • Feb 24

PEN: Proposed Cash And Stock Buyout Will Define Balanced Risk Reward Profile

Analysts have maintained their fair value estimate for Penumbra at about $348.53, with only a slight adjustment to key model inputs such as the discount rate and future P/E. This reflects updated assumptions rather than a major shift in outlook.
Aggiornamento narrativa • Feb 10

PEN: Proposed Takeover Terms And Steady Outlook Will Shape Risk Reward Balance

Analysts now hold Penumbra's fair value estimate steady at about $348.53 per share, with only slight tweaks to inputs such as the discount rate and future P/E. This reflects a largely unchanged view of the stock's risk and earnings profile.
Aggiornamento narrativa • Jan 27

PEN: Acquisition Proposal And 2025 Guidance Will Shape Future Risk Reward Balance

Analysts have raised their price target on Penumbra by about $11 per share, citing updated assumptions that include slightly higher fair value estimates, a modestly lower discount rate, and small adjustments to revenue growth, profit margin, and future P/E expectations. What's in the News Boston Scientific entered into a definitive agreement to acquire Penumbra for $14.8b, valuing each Penumbra share at $374, with stockholders able to elect cash or Boston Scientific stock, subject to proration and regulatory and shareholder approvals (M&A Transaction Announcement).
Aggiornamento narrativa • Jan 11

PEN: Trial Results And 2025 Guidance Will Shape Future Risk Reward Balance

Analysts have increased their price target on Penumbra by about $10 to reflect updated fair value assumptions, a slightly lower discount rate, modestly higher revenue growth expectations, a small adjustment to profit margin forecasts, and a higher future P/E multiple. What's in the News Penumbra updated its earnings guidance for 2025 and now expects total revenue in a range of US$1.375b to US$1.380b, based on 2024 revenue of US$1.195b, while maintaining its full year 2025 gross margin and operating margin guidance (Key Developments).
Articolo di analisi • Jan 11

Do Penumbra's (NYSE:PEN) Earnings Warrant Your Attention?

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Aggiornamento narrativa • Dec 27

PEN: Trial Data And 2025 Guidance Will Shape Future Risk Reward Balance

Analysts have modestly raised their price target on Penumbra, increasing the estimated fair value by about $18 to roughly $328 per share. This reflects slightly stronger expectations for long term revenue growth and sustainable earnings multiples, despite only marginal tweaks to discount rate and margin assumptions.
Seeking Alpha • Dec 15

Penumbra: Well-Placed For Above-Average Growth, But Mind The Volatility

Summary Penumbra offers compelling growth in mechanical thrombectomy, with strong recent results and expanding addressable markets in pulmonary embolism and neurovascular. PEN’s STORM-PE and CLOSABLE studies and upcoming Thunderbolt launch position the company for accelerated adoption and revenue growth in 2026 and beyond. Valuation remains challenging, with shares trading at high multiples, but robust growth and potential M&A interest justify a more flexible stance. I see around 10% upside at current levels, with beat-and-raise potential and long-term EBITDA margin expansion into the mid-20% range. Read the full article on Seeking Alpha
Aggiornamento narrativa • Dec 13

PEN: Clinical Trial Outcomes And 2025 Guidance Will Shape Balanced Outlook

Analysts have nudged their price target on Penumbra slightly higher, to approximately $310 per share from about $307, citing a modestly lower discount rate and a higher long term earnings multiple that more than offset a small trim to projected profit margins. What's in the News Penumbra raised its 2025 total revenue guidance to a range of $1.375 billion to $1.380 billion, implying 15% to 16% growth over 2024, while reiterating full year gross and operating margin targets (company guidance).
Articolo di analisi • Nov 28

Penumbra, Inc. (NYSE:PEN) Looks Just Right With A 27% Price Jump

Penumbra, Inc. ( NYSE:PEN ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...
Aggiornamento narrativa • Nov 21

PEN: Upcoming Clinical Results And Balanced Outlook Will Shape 2025 Performance

Analysts have modestly raised their price target for Penumbra from $306.74 to $306.79, citing incremental improvements in projected revenue growth and a slight decrease in the discount rate as key factors supporting the adjustment. What's in the News Penumbra updated its 2025 guidance, increasing expected total revenue to $1.375 to $1.38 billion, reflecting 15% to 16% growth over 2024, and maintained its gross and operating margin outlook for the year (Corporate Guidance).
Aggiornamento narrativa • Nov 07

PEN: Latest Clinical Trial Results Will Drive Global Expansion Momentum

Analysts have raised their price target for Penumbra from $303.33 to $306.74, citing modest improvements in profit margin and revenue growth forecasts. What's in the News Penumbra raised its 2025 revenue guidance to a range of $1.375 billion to $1.38 billion, representing 15% to 16% growth over 2024 figures, and reaffirmed its gross and operating margin guidance (Key Developments).
Aggiornamento narrativa • Sep 08

STORM-PE Trial And New Therapies Will Expand Global Reach

The reduction in Penumbra’s Analyst Price Target reflects a combination of weakening net profit margins and a higher future P/E multiple, with fair value revised down from $310.24 to $303.33. What's in the News Company completed repurchase of 517,763 shares (1.33%) for $100 million under the current buyback, with no shares repurchased in the latest quarter.
Seeking Alpha • Mar 13

Penumbra Off And Running On Renewed Enthusiasm For Mechanical Thrombectomy

Summary Penumbra's shares have surged again on renewed confidence in mechanical thrombectomy growth and a competitor's acquisition, but the current valuation is high at over 7x 2025 revenue estimate. Penumbra's thrombectomy business grew significantly in Q4'24, with U.S. revenue up 27% and venous revenue up 40%, driven by ongoing market penetration and share gains. Future growth looks promising with new products like Thunderbolt in stroke thrombectomy and ongoing penetration of other mechanical thrombectomy markets, but Stryker's Inari remains a formidable rival. Despite strong growth prospects, Penumbra's current valuation already reflects these expectations, making it a less than ideal candidate for GARP-type investors. Read the full article on Seeking Alpha
Seeking Alpha • Jan 07

Penumbra: Re-Rated For The Wrong Reasons

Summary Penumbra has shown significant operating leverage and profitability, with strong topline growth and a more than five-fold increase in revenue since its IPO in 2015. Despite a recent recovery in share price, growth has slowed, particularly due to challenges in China, leading to a cautious stance. Current valuation multiples have expanded, but growth expectations have softened, making the risk-reward proposition less attractive. I have sold out of my modest position due to higher expectations and slower growth, but Penumbra remains an interesting company to watch for future opportunities. Read the full article on Seeking Alpha
User avatar
Nuova narrativa • Aug 27

CAVT Technology Powers Thrombectomy Leader To Transformative Growth And Global Expansion

Introduction of CAVT technology positions Penumbra as a thrombectomy leader, driving revenue growth through innovation and market share gains.
Seeking Alpha • Aug 20

Penumbra Grinding Through A Painful Growth Expectations Reset

Summary Penumbra's stock has sold off sharply over the last year as decelerating revenue growth has spooked growth investors out of this high-multiple stock. Q2 results included 14% revenue growth, a small beat versus the Street, and improved margins, but management reduced revenue guidance by $60M (around 5%). Penumbra isn't the only player seeing a slower VTE/thrombectomy market, as Inari's business has also slowed; it's unclear what is driving the slowdown, but temporary market saturation is plausible. Penumbra's core VTE markets are only about 20% penetrated, and there are compelling arguments for using thrombectomy in eligible patients instead of anticoagulants. Penumbra is a borderline call today; I can make a case for a share price of $225, but it may take a few more quarters for the business to reaccelerate. Read the full article on Seeking Alpha
Seeking Alpha • May 30

Penumbra: Appeal Improves As Operating Leverage Continues

Summary Penumbra, a neurovascular player, has experienced solid topline growth over the past decade, now accompanied by operating leverage. Shares have fallen 20% from February levels, making them more appealing, but valuations are still demanding. The company's focus on removing clots and treating aneurysms has led to strong growth, as I am willing to dip my toes into the water on further dips. Read the full article on Seeking Alpha

Previsioni di crescita degli utili e dei ricavi

NYSE:PEN - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20282,0392763003508
12/31/20271,80024221627313
12/31/20261,5951761732409
6/30/20261,505161216278N/A
3/31/20261,454171213277N/A
12/31/20251,404178175239N/A
9/30/20251,334164153203N/A
6/30/20251,280148162201N/A
3/31/20251,24042150179N/A
12/31/20241,19514147168N/A
9/30/20241,16435134154N/A
6/30/20241,13414110128N/A
3/31/20241,09693104122N/A
12/31/20231,059918197N/A
9/30/2023995414662N/A
6/30/202393829119N/A
3/31/20238856-56-38N/A
12/31/2022847-2-75-56N/A
9/30/2022830-31-90-66N/A
6/30/2022806-19-40-17N/A
3/31/2022782-6-319N/A
12/31/20217485-1210N/A
9/30/202171034017N/A
6/30/202167116-39-23N/A
3/31/2021592-5-60-42N/A
12/31/2020560-16-58-33N/A
9/30/2020539-10-55-26N/A
6/30/202052711-34-1N/A
3/31/202055639N/A23N/A
12/31/201954748N/A27N/A
9/30/201952345N/A29N/A
6/30/201949515N/A18N/A
3/31/201947112N/A16N/A
12/31/20184457N/A29N/A
9/30/20184209N/A20N/A
6/30/201839228N/A21N/A
3/31/201836313N/A21N/A
12/31/20173345N/A13N/A
9/30/2017311-7N/A3N/A
6/30/20172945N/A-2N/A
3/31/20172799N/A-9N/A
12/31/201626315N/A-13N/A
9/30/201624518N/A-11N/A
6/30/20162286N/A-21N/A
3/31/20162053N/A-20N/A
12/31/20151861N/A-21N/A
9/30/20151670N/A-18N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di PEN ( 17.9% all'anno) è superiore al tasso di risparmio ( 3.7% ).

Guadagni vs Mercato: Si prevede che gli utili di PEN ( 17.9% all'anno) cresceranno più rapidamente del mercato US ( 16.7% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di PEN cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di PEN ( 10.9% all'anno) crescerà più lentamente rispetto al mercato US ( 12.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di PEN ( 10.9% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di PEN sarà basso tra 3 anni ( 12.8 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/08/07 17:44
Prezzo dell'azione a fine giornata2026/08/07 00:00
Utili2026/06/30
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Penumbra, Inc. è coperta da 29 analisti. 13 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
David RescottBaird
null nullBaird
Joanne WuenschBMO Capital Markets Equity Research